These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 22650305

  • 1. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
    Harikrishnan LS, Finlay HJ, Qiao JX, Kamau MG, Jiang J, Wang TC, Li J, Cooper CB, Poss MA, Adam LP, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Sitkoff DF, Galella MA, Nirschl DS, Van Kirk K, Miller AV, Huang CS, Chang M, Chen XQ, Salvati ME, Wexler RR, Lawrence RM.
    J Med Chem; 2012 Jul 12; 55(13):6162-75. PubMed ID: 22650305
    [Abstract] [Full Text] [Related]

  • 2. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX, Wang TC, Adam LP, Chen AY, Taylor DS, Yang RZ, Zhuang S, Sleph PG, Li JP, Li D, Yin X, Chang M, Chen XQ, Shen H, Li J, Smith D, Wu DR, Leith L, Harikrishnan LS, Kamau MG, Miller MM, Bilder D, Rampulla R, Li YX, Xu C, Lawrence RM, Poss MA, Levesque P, Gordon DA, Huang CS, Finlay HJ, Wexler RR, Salvati ME.
    J Med Chem; 2015 Nov 25; 58(22):9010-26. PubMed ID: 26524347
    [Abstract] [Full Text] [Related]

  • 3. Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.
    Wang Y, Yang W, Finlay HJ, Harikrishnan LS, Jiang J, Kamau MG, Van Kirk K, Nirschl DS, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Huang CS, Adam LP, Lawrence RM, Wexler RR, Salvati ME.
    Bioorg Med Chem Lett; 2014 Feb 01; 24(3):860-4. PubMed ID: 24424134
    [Abstract] [Full Text] [Related]

  • 4. Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors.
    Miller MM, Liu Y, Jiang J, Johnson JA, Kamau M, Nirschl DS, Wang Y, Harikrishnan L, Taylor DS, Chen AY, Yin X, Seethala R, Peterson TL, Zvyaga T, Zhang J, Huang CS, Wexler RR, Poss MA, Lawrence RM, Adam LP, Salvati ME.
    Bioorg Med Chem Lett; 2012 Oct 15; 22(20):6503-8. PubMed ID: 22995620
    [Abstract] [Full Text] [Related]

  • 5. 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein.
    Chen M, Yang X, Lai X, Gao Y.
    Bioorg Med Chem Lett; 2015 Oct 15; 25(20):4487-95. PubMed ID: 26346366
    [Abstract] [Full Text] [Related]

  • 6. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC.
    J Cardiovasc Pharmacol Ther; 2010 Jun 15; 15(2):196-202. PubMed ID: 20332533
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A, Prouty CP, Pelton PD, Yong M, Demarest KT, Murray WV, Kuo GH.
    Bioorg Med Chem Lett; 2010 Feb 15; 20(4):1432-5. PubMed ID: 20089400
    [Abstract] [Full Text] [Related]

  • 8. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Trieselmann T, Wagner H, Fuchs K, Hamprecht D, Berta D, Cremonesi P, Streicher R, Luippold G, Volz A, Markert M, Nar H.
    J Med Chem; 2014 Nov 13; 57(21):8766-76. PubMed ID: 25265559
    [Abstract] [Full Text] [Related]

  • 9. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety.
    Smith CJ, Ali A, Chen L, Hammond ML, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Sinclair PJ.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):346-9. PubMed ID: 19914065
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A, Mateo AI, Martin de la Nava EM, Mayhugh DR, Cockerham SL, Beyer TP, Schmidt RJ, Cao G, Zhang Y, Jones TM, Borel AG, Sweetana SA, Cannady EA, Mantlo NB.
    Bioorg Med Chem Lett; 2012 Jun 01; 22(11):3671-5. PubMed ID: 22543028
    [Abstract] [Full Text] [Related]

  • 11. Discovery of hydroxyl 1,2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors.
    Jiang J, Finlay H, Johnson JA, Harikrishnan L, Kamau M, Qiao J, Wang T, Adam L, Taylor D, Yang R, Sleph P, Chen AYA, Yin X, Wexler R, Salvati ME.
    Bioorg Med Chem Lett; 2016 Jul 15; 26(14):3278-3281. PubMed ID: 27256912
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.
    Finlay HJ, Jiang J, Rampulla R, Salvati ME, Qiao JX, Wang TC, Lawrence RM, Harikrishnan LS, Kamau MG, Taylor DS, Chen AYA, Yin X, Huang CS, Chang M, Chen XQ, Sleph PG, Xu C, Li J, Levesque P, Adam LP, Wexler RR.
    ACS Med Chem Lett; 2019 Jun 13; 10(6):911-916. PubMed ID: 31223447
    [Abstract] [Full Text] [Related]

  • 13. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
    Blasi E, Bamberger M, Knight D, Engwall M, Wolk R, Winter S, Betts A, John-Baptiste A, Keiser J.
    J Cardiovasc Pharmacol; 2009 Jun 13; 53(6):507-16. PubMed ID: 19455053
    [Abstract] [Full Text] [Related]

  • 14. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
    Kallashi F, Kim D, Kowalchick J, Park YJ, Hunt JA, Ali A, Smith CJ, Hammond ML, Pivnichny JV, Tong X, Xu SS, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Peterson LB, Rosa R, Sparrow CP, Wright SD, Sinclair PJ.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):558-61. PubMed ID: 21094047
    [Abstract] [Full Text] [Related]

  • 15. Chromanol derivatives--a novel class of CETP inhibitors.
    Vakalopoulos A, Schmeck C, Thutewohl M, Li V, Bischoff H, Lustig K, Weber O, Paulsen H, Elias H.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):488-91. PubMed ID: 21084191
    [Abstract] [Full Text] [Related]

  • 16. HDL metabolism and CETP inhibition.
    Barkowski RS, Frishman WH.
    Cardiol Rev; 2008 Jan 01; 16(3):154-62. PubMed ID: 18414186
    [Abstract] [Full Text] [Related]

  • 17. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ.
    Am J Cardiol; 2007 Dec 03; 100(11 A):n47-52. PubMed ID: 18047853
    [Abstract] [Full Text] [Related]

  • 18. Novel tetrahydrochinoline derived CETP inhibitors.
    Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz G, Weber O.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1740-3. PubMed ID: 20137927
    [Abstract] [Full Text] [Related]

  • 19. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.
    Cardiovasc Ther; 2011 Dec 01; 29(6):e89-99. PubMed ID: 20645987
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
    Fernandez MC, Escribano A, Mateo AI, Parthasarathy S, Martin de la Nava EM, Wang X, Cockerham SL, Beyer TP, Schmidt RJ, Cao G, Zhang Y, Jones TM, Borel A, Sweetana SA, Cannady EA, Stephenson G, Frank S, Mantlo NB.
    Bioorg Med Chem Lett; 2012 May 01; 22(9):3056-62. PubMed ID: 22497761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.